Skip to main content

Table 2 Event rates per 100 patient-years (py) for the outcomes thromboembolic events, death and bleeding before and after propensity-score matching

From: Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data

 

Phenprocoumon

Ld-DOAC

Event rate per 100 py

Before matching

After matching

Before matching

After matching

n

20,179

14,818

21,724

14,818

 Thromboembolic events

2.53

2.83

4.42

3.93

 Deceased

7.45

8.57

18.51

15.01

 Bleeding

4.05

4.53

4.61

4.22

 

Phenprocoumon

Ld-Apixaban

Event rate per 100 py

Before matching

After matching

Before matching

After matching

n

20,179

8991

10,997

8991

 Thromboembolic events

2.53

3.19

5.18

4.87

 Deceased

7.45

11.37

22.55

19.32

 Bleeding

4.05

5.31

4.26

4.12

 

Phenprocoumon

Ld-Dabigatran

Event rate per 100 py

Before matching

After matching

Before matching

After matching

n

20,179

1908

1914

1908

 Thromboembolic events

2.53

3.09

3.59

3.59

 Deceased

7.45

9.42

9.49

9.23

 Bleeding

4.05

3.66

3.52

3.52

 

Phenprocoumon

Ld-Edoxaban

Event rate per 100 py

Before matching

After matching

Before matching

After matching

n

20,179

2235

2255

2235

 Thromboembolic events

2.53

3.23

3.74

3.78

 Deceased

7.45

11.34

16.07

15.76

 Bleeding

4.05

4.98

4.84

4.82

 

Phenprocoumon

Ld-Rivaroxaban

Event rate per 100 py

Before matching

After matching

Before matching

After matching

n

20,179

6478

6558

6478

 Thromboembolic events

2.53

2.90

3.60

3.55

 Deceased

7.45

9.51

14.96

14.67

 Bleeding

4.05

4.83

5.48

5.35

  1. Event rates before and after propensity-score matching in phenprocoumon cohort, composite low-dose DOAC (ld-DOAC) cohort and single ld-DOAC cohorts (ld-apixaban, ld-dabigatran, ld-edoxaban and ld-rivaroxaban)